Preoperative induction chemotherapy with cisplatin and irinotecan for pathological N2 non-small cell lung cancer

[1]  F. Grannis.  Comment on Rosell et al., Roth et al. and Gandara et al., Lung Cancer. , 2000, Lung cancer.

[2]  J. Padilla,et al.  Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized controlled trial. , 1999, Lung cancer.

[3]  K. Kiura,et al.  Fractionated administration of irinotecan and cisplatin for treatment of lung cancer: a phase I study , 1999, British Journal of Cancer.

[4]  横山 晶.  Dose finding study of irinotecan and cisplatin plus concurrent radiotherapy for unresectable stage III non-small-cell lung cancer , 1999 .

[5]  J. Ciezki,et al.  Short-course induction chemoradiotherapy with paclitaxel for stage III non-small-cell lung cancer. , 1998, The Annals of thoracic surgery.

[6]  J. Roth,et al.  Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. , 1998, Lung cancer.

[7]  N. Choi,et al.  Assessment of preoperative accelerated radiotherapy and chemotherapy in stage IIIA (N2) non-small-cell lung cancer. , 1996, The Journal of thoracic and cardiovascular surgery.

[8]  J. Crowley,et al.  Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  D. Sugarbaker,et al.  Results of cancer and leukemia group B protocol 8935. A multiinstitutional phase II trimodality trial for stage IIIA (N2) non-small-cell lung cancer. Cancer and Leukemia Group B Thoracic Surgery Group. , 1995, The Journal of thoracic and cardiovascular surgery.

[10]  W. Curran,et al.  Postoperative complications after combined neoadjuvant treatment of lung cancer. , 1993, The Annals of thoracic surgery.

[11]  J. Crowley,et al.  Surgical resection of stage IIIA and stage IIIB non-small-cell lung cancer after concurrent induction chemoradiotherapy. A Southwest Oncology Group trial. , 1993, The Journal of thoracic and cardiovascular surgery.

[12]  L. Liu,et al.  Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. , 1988, Cancer research.

[13]  E. McFadden,et al.  Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.

[14]  J. Cooper,et al.  Significance of positive superior mediastinal nodes identified at mediastinoscopy in patients with resectable cancer of the lung. , 1982, The Journal of thoracic and cardiovascular surgery.